Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14c}-GSK1349572 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | \[14C\]-GSK1349572 administered as a single oral dose |
| Name | Type | Description |
|---|---|---|
| [14c}-GSK1349572 | DRUG | HIV-Integrase inhibitor labelled with a carbon 14 marker |
Inclusion Criteria: * Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. * Male subjects between 30 and 55 years of age. * Male subjects must agree to use one of the contraception ...
14c-GSK1349572 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed mass balance study. The drug is not approved and remains under investigation for its potential use.
14c-GSK1349572 is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate this investigational small molecule.
14c-GSK1349572 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 mass balance study has been completed as part of its early-stage evaluation.
14c-GSK1349572 has one completed clinical trial, registered as NCT00828763. This Phase 1 study, titled 'GSK1349572 Mass Balance Study,' enrolled 6 healthy male volunteers in the United States. The trial was uncontrolled and not randomized or double-blinded.
Yes, 14c-GSK1349572 is a radiolabeled form of GSK1349572, used in a mass balance study to track the drug's absorption, distribution, metabolism, and excretion in the body. The clinical trial NCT00828763 specifically investigated this labeled version.